Ocuphire Pharma Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

NDA Supported by Positive Phase 3 Data Demonstrating Rapid Reversal of Dilated Eyes and Favorable Safety Profile in Pediatric and Adult Subjects FARMINGTON HILLS, Mich., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news